SHANGHAI FUDAN H YC-,10 (FDY) - Net Assets
Based on the latest financial reports, SHANGHAI FUDAN H YC-,10 (FDY) has net assets worth €2.28 Billion EUR (≈ $2.67 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.54 Billion ≈ $2.97 Billion USD) and total liabilities (€261.02 Million ≈ $305.15 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SHANGHAI FUDAN H YC-,10 liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.28 Billion |
| % of Total Assets | 89.73% |
| Annual Growth Rate | 1.73% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2.94 |
SHANGHAI FUDAN H YC-,10 - Net Assets Trend (2021–2024)
This chart illustrates how SHANGHAI FUDAN H YC-,10's net assets have evolved over time, based on quarterly financial data. Also explore SHANGHAI FUDAN H YC-,10 (FDY) total assets for the complete picture of this company's asset base.
Annual Net Assets for SHANGHAI FUDAN H YC-,10 (2021–2024)
The table below shows the annual net assets of SHANGHAI FUDAN H YC-,10 from 2021 to 2024. For live valuation and market cap data, see SHANGHAI FUDAN H YC-,10 stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €2.31 Billion ≈ $2.70 Billion |
-2.26% |
| 2023-12-31 | €2.36 Billion ≈ $2.76 Billion |
+4.68% |
| 2022-12-31 | €2.25 Billion ≈ $2.63 Billion |
+2.90% |
| 2021-12-31 | €2.19 Billion ≈ $2.56 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SHANGHAI FUDAN H YC-,10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €864.75 Million | 37.52% |
| Other Components | €1.44 Billion | 62.48% |
| Total Equity | €2.30 Billion | 100.00% |
SHANGHAI FUDAN H YC-,10 Competitors by Market Cap
The table below lists competitors of SHANGHAI FUDAN H YC-,10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Smith & Nephew PLC
LSE:SN
|
$118.48 Million |
|
Apollo Food Holdings Bhd
KLSE:6432
|
$118.50 Million |
|
Yibitas Yozgat Isci Birligi Insaat Malzemeleri Ticaret Sanayi AS
IS:YBTAS
|
$118.53 Million |
|
Gabelli Global Utility & Income Tr
NYSE MKT:GLU
|
$118.55 Million |
|
Diamond Building Products Public Company Limited
BK:DRT
|
$118.45 Million |
|
Quantum Foods Holdings
JSE:QFH
|
$118.45 Million |
|
BEC World Public Company Limited
BK:BEC
|
$118.44 Million |
|
American Lithium Corp
V:LI
|
$118.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SHANGHAI FUDAN H YC-,10's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,357,553,851 to 2,304,567,412, a change of -52,986,439 (-2.2%).
- Net income of 39,733,896 contributed positively to equity growth.
- Dividend payments of 93,291,489 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €39.73 Million | +1.72% |
| Dividends Paid | €93.29 Million | -4.05% |
| Other Changes | €571.15K | +0.02% |
| Total Change | €- | -2.25% |
Book Value vs Market Value Analysis
This analysis compares SHANGHAI FUDAN H YC-,10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.13x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.10 | €0.30 | x |
| 2022-12-31 | €2.19 | €0.30 | x |
| 2023-12-31 | €2.26 | €0.30 | x |
| 2024-12-31 | €2.21 | €0.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SHANGHAI FUDAN H YC-,10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.60%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.12x
- Recent ROE (1.72%) is below the historical average (5.54%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 9.73% | 18.71% | 0.41x | 1.27x | €-6.00 Million |
| 2022 | 6.11% | 13.38% | 0.35x | 1.32x | €-87.71 Million |
| 2023 | 4.61% | 12.77% | 0.30x | 1.22x | €-127.13 Million |
| 2024 | 1.72% | 5.60% | 0.27x | 1.12x | €-190.72 Million |
Industry Comparison
This section compares SHANGHAI FUDAN H YC-,10's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $796,231,369
- Average return on equity (ROE) among peers: -46.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SHANGHAI FUDAN H YC-,10 (FDY) | €2.28 Billion | 9.73% | 0.11x | $118.45 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $6.65 Billion | 14.85% | 0.54x | $692.11 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $2.69 Million | -197.11% | 3.73x | $113.81K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-815.79K | 0.00% | 0.00x | $134.78K |
| EQL PHARMA AB (7JK) | $154.75 Million | 19.98% | 0.85x | $148.83 Million |
| Alkermes plc (8AK) | $1.11 Billion | -4.33% | 0.82x | $5.00 Billion |
| OPTIMI HEALTH CORP. (8BN) | $16.02 Million | -45.89% | 0.05x | $17.99 Million |
| LABIANA HEALTH S.A.EO-10 (8RK) | $3.40 Million | -129.96% | 16.37x | $40.60 Million |
| CANNABIS POLAND AB ZY-10 (8TE) | $1.36 Million | -85.24% | 0.35x | $1.75 Million |
| Apontis Pharma AG (APPH) | $30.26 Million | -37.35% | 0.90x | $91.63 Million |
| CRAFTPORT CANNABIS CORP. (BBW0) | $-3.18 Million | 0.00% | 0.00x | $1.45 Million |
About SHANGHAI FUDAN H YC-,10
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clini… Read more